Repligen Corp (NASDAQ:RGEN)

US · Delayed Price · Currency is USD

Healthcare · Medical - Instruments & Supplies

Full ChartAlerts Compare

178.32+1.39 (+0.78%)

Market cap

$11.3B

Analyst consensus

Buy

Listed since

Apr 29, 1986

Website

repligen.com

Insider Score

––Not scored

RGEN Insider Score

Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.

See stocks that are scored

RGEN Income Statement

Fiscal Period	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025
Period Ending	Jun 30, 2026	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025
Revenue	204.13 M	194.25 M	197.91 M	188.81 M	182.37 M	169.17 M
Revenue Growth (YoY)	11.93 %	14.83 %	18.12 %	21.91 %	14.81 %	10.44 %
Cost of Revenue	95.77 M	95.77 M	104.47 M	88.29 M	91.22 M	78.42 M
Gross Profit	108.36 M	98.48 M	93.44 M	100.52 M	91.14 M	90.76 M
SG&A Expense	76.62 M	76.54 M	62.70 M	73.66 M	71.23 M	71.25 M
R&D Expense	14.42 M	14.46 M	12.18 M	14.18 M	13.96 M	12.92 M
Operating Expenses	96.43 M	80.49 M	74.89 M	83.69 M	77.25 M	84.18 M
Operating Income	11.93 M	17.99 M	18.56 M	16.82 M	13.90 M	6.58 M
Pretax Income	14.15 M	1.77 M	19.11 M	17.11 M	18.21 M	7.94 M
Tax Provision	9.14 M	-6.56 M	5.83 M	2.20 M	3.35 M	2.11 M
Net Income	5.01 M	8.33 M	13.29 M	14.91 M	14.87 M	5.83 M
EPS (Basic)	0.09	0.15	0.23	0.27	0.26	0.10
EPS (Diluted)	0.09	0.15	0.23	0.26	0.26	0.10
Shares Outstanding	56.39 M	56.35 M	56.52 M	56.21 M	56.18 M	56.12 M

Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.